- Medtronic reported fiscal Q1 revenue of $9.8 billion and adjusted EPS of $1.45, with revenue up 13.7% on both a reported and organic basis.
- Medtronic posted 13.7% organic sales growth, roughly 200 basis points above the midpoint of its guidance, while cardiovascular and medical-surgical sales topped forecasts.
- Medtronic and its diabetes spinoff Minimed raised full-year guidance, sending both stocks higher.